Agios officer Sarah Gheuens proposes 1,489-share sale

Sarah Gheuens also reported 30,000 common shares sold on August 4, 2026, for $914,283.00 during the preceding three months.

Rhea-AI Filing Summary

Agios Pharmaceuticals officer Sarah Gheuens reported a proposed sale of 1,489 common shares, with October 21, 2026, listed as the approximate sale date. The proposed sale is listed through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate aggregate market value of $55,881.28. The shares were acquired through a stock option exercise from the issuer for cash.

Key Figures

Proposed sale: 1,489 common shares Approximate aggregate market value: $55,881.28 Shares sold in prior three months: 30,000 common shares +1 more

4 metrics

Proposed sale 1,489 common shares Approximate sale date October 21, 2026

Approximate aggregate market value $55,881.28 Proposed sale of 1,489 common shares

Shares sold in prior three months 30,000 common shares Sold August 4, 2026

Aggregate value of prior sales $914,283.00 Shares sold August 4, 2026

Key Terms

Rule 144, Stock Option Exercise, Securities To Be Sold

3 terms

Rule 144 regulatory

"definition of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Stock Option Exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Securities To Be Sold regulatory

"Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AGIO shares is Sarah Gheuens proposing to sell?

Sarah Gheuens reported a proposed sale of 1,489 common shares, with October 21, 2026, listed as the approximate sale date. The approximate aggregate market value is $55,881.28.

How many AGIO shares did Sarah Gheuens sell in the prior three months?

Sarah Gheuens reported selling 30,000 common shares on August 4, 2026, for $914,283.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 05:32 PM EDT Accepted by SEC EDGAR 10/21/2026 - 05:32 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001881190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AGIOS PHARMACEUTICALS, INC.
SEC File Number	001-36014
Address of Issuer	88 Sidney St. Cambridge MASSACHUSETTS 02139
Phone	617-649-8600
Name of Person for Whose Account the Securities are To Be Sold	SARAH GHEUENS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1489	55881.28	59701882	10/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/21/2026	Stock Option Exercise	Issuer			1489	10/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SARAH GHEUENS 88 Sidney St. Cambridge MA 02139	Common	08/04/2026	30000	914283.00

144: Remarks and Signature

Remarks
Date of Notice	10/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/01/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sarah Gheuens
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)